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Abstract Apolipoproteins A-II and C-III, which participate in 
the control of cholesterolemia and triglyceridemia, are negative 
acute phase proteins. Treatment of HepG2 cells with TNFa 
showed that apoA-II and apoC-ΠΙ mRNA levels were decreased. 
Using transient transfection, we found that apoC-III gene 
expression is controlled at the transcriptional level. By competi-
tion and supershift experiments, we demonstrate that TNFa-
induced complexes were related to C/EBPo7NF-IL6ß and p50 
and that overexpression of C/ΕΒΡδ was able to reproduce the 
inhibitory effect of TNFa on the apoC-ΙΠ promoter. RT-PCR 
failed to detect the IL-1 transcript in TNFa-treated HepG2 cells, 
suggesting that activation of C/ΕΒΡδ by TNFa is not related to 
the IL-1-signalling pathway. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
After trauma, infection, or inflammation, two classes of 
acute phase proteins (APP) may be identified: positive 
APPs, such as C-reactive protein and serum amyloid A 
(SAA) protein, whose plasma concentrations increase during 
inflammation [1], and negative ones, such as albumin and 
apolipoproteins (apo), whose levels decrease [2]. The acute 
phase response is mediated by cytokines, such as interleu-
kin-1 (IL-1), IL-6, and tumor necrosis factor a (TNFa). These 
cytokines affect gene expression by acting at different levels, 
particularly by controlling the functional activity of several 
transcription factors. Among the transcription factors known 
to be activated by TNFa are the early response gene c-jun [3], 
the ubiquitous factor Spl [4], and the NF-κΒ transcription 
factor [5]. Whereas the induction of positive APPs has been 
well studied, little is known about the regulation of negative 
APPs. Previous findings have demonstrated that the down-
regulation of negative acute phase genes involves post-tran-
scriptional mechanisms [6] or a decrease in the expression of a 
positive transactivator [7]. Since it has been previously re-
ported that apoC-III and apoA-II are decreased during infec-
tion and inflammation in humans and rats [8,9], we decided to 
investigate the regulation of the expression of these two genes 
by TNFa in HepG2, a human hepatoma cell line. We found 
that TNFa activates C/EBP8/NF-IL6ß and p50, and that C/ 
ΕΒΡδ had a dominant negative effect on apoC-III promoter. 
Corresponding author. Fax: (33) (0) 1 43 25 16 15. 
2. Materials and methods 
2.1. Cell culture and transfections 
HepG2 cells (4xl05) were transfected by the calcium phosphate-
DNA coprecipitation method [10] with a mixture of DNAs containing 
7 μg of reporter chloramphenicol acetyltransferase (CAT) plasmid, 
apoC-III-890-CAT or -911/+29 A-II CAT [11,12], 2 μg of 
pCMVßGal plasmid, and 0.25-1 μg of expression vector and carrier 
plasmid added to keep the total amount of DNA constant at 10 μg. 
The C/ΕΒΡδ expression vector, generously provided by G. Ciliberto, 
was subcloned into the pCB6 vector [13]. RcCMV p50 was the kind 
gift of L. Schmitz. CAT assays were carried out in liquid phase, as 
previously described [14], and normalized for ß-galactosidase activity. 
Human recombinant TNFa (R&D, Abingdon, UK) was added im-
mediately after transfection. 
2.2. RNA analysis 
Total RNA was extracted with RNAzol (Bioprobe, Montreuil-sous-
Bois, France). RNAs from untreated and TNFa-treated HepG2 cells 
were separated on formaldehyde containing 1.2% agarose gel. After 
transfer, the blots were hybridized with hapoC-III, hapoA-II, and 18S 
cDNA probes radiolabeled by the random priming method. Prehy-
bridization, hybridization, and washing were carried out as described 
previously [15]. Specific hybridization signals were visualized by auto-
radiography and quantified by densitometry. Isolation of macro-
phages was carried out as previously described [16]. For detection 
of IL-lß mRNA by RT-PCR, 1 μg of total RNA was reverse-tran-
scribed and amplified as previously described [16]. As a control of the 
reverse transcription reaction, amplification of ß-actin cDNA was 
carried out on the same cDNA that was used to amplify the IL-1 
transcript [17]. 
2.3. Nuclear extract preparation and in vitro DNA binding assays 
Nuclear proteins were extracted as previously described [18], except 
that 50 mM NaF was added in all buffers. Electrophoretic mobility 
shift assays (EMSA) were carried out as previously described [19] with 
oligonucleotides CHID: 5'-CTCAGTCTCCTAGGGATTTCCCAA-
CTCTCCCGCCC [11] and AlbD: 5'-TGGTATGATTTTGTAAT-
GGGGTAGGGA [20]. In supershift experiments, nuclear extracts 
were pre-incubated for 4 h at 4°C with 1 μΐ of the following anti-
bodies: anti-C/EBPa, anti-C/ΕΒΡδ, anti-c-rel (Santa Cruz), anti-
C/EBPß (gift of S.-C. Lee), anti-p65, and anti-p50 (kindly provided 
by A. Israel) prior to the binding reaction. 
3. Results 
Fig. 1A shows that TNFa treatment of HepG2 cells re-
sulted in a decrease in apoC-III and apoA-II mRNA accumu-
lation. We observed a twofold decrease in apoC-III and 
apoA-II mRNA after 24 h as well as 8 h (data not shown) 
of incubation with 10 ng of TNFa. In order to determine 
whether this inhibition was exerted at the transcriptional level, 
HepG2 cells were transiently transfected with apoC-III-890-
CAT or -911/+29 A-II CAT plasmids and stimulated by 
TNFa. The region between -890 and +24 of the apoC-III 
gene and the region between —911 and +29 of the apo A-II 
gene contain all the regulatory elements required for tissue-
specific expression and nutritional and hormonal control 
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Fig. 1. Inhibition of apoC-III and apoA-II gene expression by 
TNFa. A: 30 μg of total RNA from HepG2 cells treated with 1, 
10, or 100 ng/ml TNFa for 24 h was analyzed by Northern blotting 
and hybridized with apoC-III and apoA-II cDNA probes. After 
densitometric quantification and normalization with the 18S probe, 
apoC-III and apoA-II mRNA levels were expressed as a percentage 
of normalized values measured in untreated cells. B: HepG2 cells 
were transfected with apoC-III-890-CAT or -911/+29 A-II CAT 
promoter constructs and treated with (white column) or without 
(black column) 10 ng of TNFa for 36 h. Results are expressed as 
the mean values ± S.D. of the normalized chloramphenicol acetyl-
transferase activity of three independent experiments. 
[11,21,22]. As shown in Fig. IB, 24 h of TNFa treatment 
induced a twofold inhibition of apoC-III promoter activity, 
which suggests that TNFa inhibits apoC-III gene expression 
at the transcriptional level (if not also post-transcriptionally). 
We did not observe any significant change in CAT gene ex-
pression under the control of the —911/+29 apoA-II pro-
moter. This could indicate either that the —911/+29 promoter 
region does not comprise the TNFa responsive element con-
trolling apoA-II transcription or that TNFa inhibits apoA-II 
gene expression at the post-transcriptional level. We could not 
assess the effect of TNFa on apolipoprotein mRNA stability, 
since actinomycin D (5 ng/ml) dramatically increases TNFa 
cytotoxicity, as has been previously reported [23]. 
We focused our attention on the transcriptional repression 
of apoC-III. Previous studies have shown that the element D 
(between —160 and —142) of the apoC-III promoter could 
bind N F - K B [24] and C/EBP [25]. Therefore we compared 
the EMSA patterns of nuclear extracts of cells treated with 
TNFa for 4 h with those of untreated cells. Gel retardation 
assays that were carried out with untreated cell nuclear ex-
tracts formed two broad complexes, CIIID1 and CIIID2 (Fig. 
2A). These complexes were related to members of the C/EBP 
family, since the AlbD oligonucleotide, a high-affinity binding 
site for C/EBP [20], competed with them. We demonstrated by 
supershift experiments that CIIID1 and CIIID2 were formed 
by heteroduplexes containing C/ΕΒΡα and C/EBPß [26]. In 
addition to CIIID1 and CIIID2, nuclear extracts from 
TNFa-treated cells revealed a third, faster-migrating complex, 
CIIID3, also displaced by AlbD, and two other binding com-
plexes, designated a and b, which were not displaced by an 
excess of the AlbD domain (Fig. 2A). CIIID3 consisted only 
of C/EBPö/NF-IL6ß and none of the other factors tested, e.g. 
C/ΕΒΡα, C/EBPß (Fig. 2B), p65, p50, and c-rel (data not 
shown). On the other hand, the a complex was supershifted 
by anti-p50 and partially by anti-p65 but not by anti-c-rel 
(Fig. 2C), nor by anti-C/ΕΒΡα, anti-C/EBPß or anti-C/ΕΒΡδ 
(data not shown), suggesting that a complex could be a p50/ 
p65 heterodimer. In contrast, the b complex was only super-
shifted by anti-p50 and not by any other antibodies against 
members of the NF-κΒ family (Fig. 2C) or the C/EBP family 
(data not shown), suggesting that the b complex is made of 
p50 subunits. These results provide evidence that TNFa acti-
vates binding of three different transcriptional factors that 
belong to distinct families. 
The activation of p50 and C/ΕΒΡδ in HepG2 cell nuclei 
after TNFa induction prompted us to evaluate the functional 
role of these factors on the apoC-III promoter. As shown in 
Fig. 3, C/ΕΒΡδ inhibited apoC-III transcription, reproducing 
the inhibitory effect of TNFa. In contrast, p50 induced pos-
itive transactivation of the apoC-III promoter. In order to 
assess the resulting transactivation effect of C/ΕΒΡδ and p50 
on apoC-III transcription, we carried out cotransfection ex-
periments. As shown in Fig. 3A, addition of C/ΕΒΡδ reversed 
positive transactivation by p50. On the other hand, the repres-
sive effect of C/ΕΒΡδ was not affected by transfection of in-
creasing amounts of p50 (Fig. 3B). The above results suggest a 
dominant negative role of C/ΕΒΡδ on p50 in the control of 
apoC-III gene transcription during TNFa incubation. 
Several studies have shown that IL-1 can activate C/ΕΒΡδ 
[27,28]. Furthermore, it has been demonstrated that hepato-
cytes and hepatoma cell lines are able to synthesize IL-1 
[29,30]. Therefore, one could hypothesize that TNFa induces 
IL-1 secretion in HepG2 cells, which in turn could activate C/ 
ΕΒΡδ. In order to detect IL-1 mRNA, we carried out RT-
PCR, using IL-lß primers [16]. As shown in Fig. 4, IL-lß 
cDNA (391 bp) was detected in macrophages (lane 1) but 
not in TNFa-treated or untreated HepG2 cells (lanes 2 and 
3). This suggests that IL-lß was not synthesized by HepG2 
cells exposed to TNFa before activation of C/EBPö/NF-IL6ß 
and that this activation proceeded via an independent IL-1 
pathway. 
4. Discussion 
The acute phase of the inflammatory response is character-
ized by wide-ranging physiological changes, particularly by an 
altered pattern of protein synthesis in the liver characterized 
by increased or decreased plasma levels of APPs. These phys-
iological responses are initiated and coordinated by various 
inflammatory mediators, including cytokines, such as IL-1, 
IL-6, and TNFa. The main effect of cytokines in APP expres-
sion is due to modifications in gene transcription. However, 
post-transcriptional events may also contribute to altered 
plasma APP. Until now, only a few transcription factors, 
such as c-jun, Spl, and NF-κΒ, have been reported to be 
functionally activated by TNFa. Our findings provide evi-
dence, for the first time, that NF-IL6ß, the human homolog 
of C/ΕΒΡδ, is activated by TNFa, a pro-inflammatory cyto-
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Fig. 2. TNFa treatment activates DNA binding of C/ΕΒΡδ and p50. Nuclear extracts prepared from cells treated for 4 h with TNFa, as well 
as those of untreated cells, were analyzed by means of EMSA, using the double-stranded CHID oligonucleotide, in the presence or absence of 
a 100-fold molar excess of cold competitor AlbD (panel A) in the presence of anti-C/ΕΒΡα, anti-C/EBPß or anti-C/ΕΒΡδ antibodies (panel B) 
or in the presence of a 100-fold molar excess of cold AlbD competitor and antibodies raised against members of the NF-κΒ family (panel C). 
kine, in the HepG2 human hepatoma cell line. We and others 
have reported that, in addition to IL-6, C/ΕΒΡδ is activated 
by IL-lß, inducing an increase in mRNA and protein [26,27]. 
Since it is possible that C/ΕΒΡδ was activated by the IL-1 
secretion of hepatoma cells induced by TNFa, we decided 
to look for IL-lß mRNA following TNFa treatment. After 
4 h of incubation with TNFa, the mRNA of IL-lß in HepG2 
cells was not detected, whereas C/EBP5/NF-IL6ß binding was 
activated. Therefore, in addition to IL-6 and IL-1, we found 
that TNFa is able to activate C/ΕΒΡδ by its own pathway, 
which attributes a central role to this transcriptional factor in 
the regulation of the acute phase of inflammation. 
Decreased expression of transactivator [7] and post-tran-
scriptional control [6] have been implicated in the regulation 
of negative APP expression. In the present study we further 
assess our recent observation that in the context of apoC-III 
Fig. 3. Negative dominant effect of C/ΕΒΡδ on apoC-III transcrip-
tion. HepG2 cells were co-transfected with apoC-III-890-CAT and 
various quantities of C/ΕΒΡδ and p50 expression vectors. CAT val-
ues measured in the cotransfection experiments are expressed as the 
percentage of apoC-III promoter activity alone. 
Fig. 4. Absence of IL-lß mRNA in TNFa-treated HepG2 cells. 
Ethidium bromide-stained agarose gel of PCR experiments. 1 μg of 
RNA from cells treated with TNFa for 4 h (lane 3) and from un-
treated cells (lanes 1 and 2) was reverse-transcribed and amplified 
by PCR, using IL-lß primers (A) or ß-actin primers (B). 
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promoter, C/ΕΒΡδ acts as a repressor of transcription [26]. In 
that study we showed that this inhibition is not mediated by 
the D and C domains, which are able to bind C/EBP, but 
rather by the I domain, located in the enhancer region, where 
it cannot bind [26]. We suggest that C/ΕΒΡδ, but not C/EBPa, 
disrupts the transcriptional complex by a protein-protein in-
teraction. Moreover, in the present study, we demonstrate 
that TNFoc, in addition to C/ΕΒΡδ, activates binding of p50 
in HepG2 cells which has a positive transactivation effect on 
the apoC-III promoter. p50 belongs to a family which con-
tains the Rel domain, required for DNA binding, as well as to 
form homodimers and heterodimers with other Rel family 
proteins [31]. A previous study has reported that p50 can 
interact physically and functionally with members of the C/ 
EBP family [32]. Cotransfection of C/ΕΒΡδ with p50 revealed 
that the inhibitory effect of C/ΕΒΡδ predominates over the 
positive effect of p50 on the apoC-III promoter. The physio-
logical relevance of the activation of p50 on the expression of 
the apoC-III gene remains to be elucidated. 
Since its discovery, C/EBPö/NF-IL6ß has been implicated 
in the induction of several positive APPs [33,34]. The binding 
and transactivating capacities of C/ΕΒΡδ have recently been 
reported to depend on tyrosine and serine/threonine phos-
phorylation [26,35]. Our results agree with these findings, 
since the omission of sodium fluoride, which is a phosphatase 
inhibitor, in the nuclear extract buffer markedly decreases the 
binding activity of C/ΕΒΡδ (data not shown). Several recent 
reports suggest that protein kinases are activated playing a 
critical role in the TNFot signalling pathway (review in [36]), 
raising the possibility of the direct activation of C/ΕΒΡδ by 
the signal-transducing protein kinase cascade triggered by 
TNFoc. These results have led us to suggest that C/ΕΒΡδ could 
play a pivotal role in the acute phase reaction by exercising 
transcriptional control over positive and negative APPs. The 
activation of C/ΕΒΡδ could possibly disrupt or enhance the 
actions of transcriptional complexes by interfering with tran-
scription factors, leading to an increase or a decrease in tran-
scription. The mechanism involved in this regulation may be a 
protein-protein interaction which could be modulated by the 
phosphorylation status of C/ΕΒΡδ. Therefore, C/ΕΒΡδ is ca-
pable of inducing a high level of transcription of positive 
APPs and at the same time of repressing apoC-III gene ex-
pression. 
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